PDF(Pubmed)
Abstract：
HR810 is a new, very broad-spectrum cephalosporin with significant activity against members of the family Enterobacteriaceae, pseudomonads, gram-positive cocci, and anaerobes that is generally greater than the third-generation cephalosporins (99.6% of 4,128 clinical facultative enteric isolates were inhibited by less than or equal to 8.0 micrograms of HR810 per ml). Tests and statistical methods to establish in vitro antimicrobial susceptibility test criteria favor tentative breakpoints of greater than or equal to 18 mm (less than or equal to 8.0 micrograms/ml) as susceptible and less than or equal to 14 mm (greater than or equal to 32 micrograms/ml) as resistant. This provides a 93.7 to 98.3% absolute interpretive accuracy. Several preliminary ranges for zone sizes obtained with quality control organisms are proposed for the 30-micrograms HR810 disk diffusion test used during the clinical trials.
摘要：
HR810是一个新的，非常广谱的头孢菌素，对肠杆菌科的成员具有显著的活性，pseudomonads,革兰氏阳性球菌,和厌氧菌通常大于第三代头孢菌素（4,128例临床兼性肠道分离物中的99.6％被小于或等于8.0微克HR810/ml抑制）。建立体外抗微生物药敏试验标准的测试和统计方法有利于大于或等于18毫米（小于或等于8.0微克/毫升）的暂定断点作为敏感和小于或等于14毫米（大于或等于32微克/毫升）作为抗性。这提供了93.7至98.3%的绝对解释准确度。对于临床试验中使用的30微克HR810圆盘扩散测试，提出了使用质量控制生物获得的区域大小的几个初步范围。
